Department of Medical Physics, Tabriz University of Medical Sciences School of Medicine, Tabriz, Iran.
J Breast Cancer. 2012 Jun;15(2):141-7. doi: 10.4048/jbc.2012.15.2.141. Epub 2012 Jun 28.
Breast cancer is the most common malignancy, and it is also the major cause of cancer-related deaths of women worldwide. Breast cancer treatment involves surgery, chemotherapy, radiation therapy, or combination therapy, and novel strategies are needed to boost the oncologic outcome. The non-metabolizable glucose analogue, 2-deoxy-D-glucose (2-DG) which inhibits glucose synthesis and adenosine triphosphate production, is one of the important discoveries involving the disturbances that can be caused to the process of the metabolism. The glucose analogue, 2-DG, is known as a tumor sensitizer to irradiation (IR) and chemotherapy, which help improve the treatment rates. It enhances the cytotoxicity via oxidative stress, which is more redundant in tumor cells than in normal ones. This article provides a brief summary on studies related to 2-DG chemo-/radio-sensitization effects by combination therapy of 2-DG/IR or 2-DG/doxorubicin.
乳腺癌是最常见的恶性肿瘤，也是全球女性癌症相关死亡的主要原因。乳腺癌的治疗包括手术、化疗、放疗或联合治疗，需要新的策略来提高肿瘤治疗效果。非代谢型葡萄糖类似物 2-脱氧-D-葡萄糖（2-DG）可抑制葡萄糖合成和三磷酸腺苷产生，这是涉及代谢过程中可引起干扰的重要发现之一。葡萄糖类似物 2-DG 被称为辐射（IR）和化疗的肿瘤增敏剂，有助于提高治疗率。它通过氧化应激增强细胞毒性，而肿瘤细胞中的氧化应激比正常细胞更为多余。本文简要总结了 2-DG/IR 或 2-DG/多柔比星联合治疗的 2-DG 化疗/放疗增敏作用的相关研究。
